title: LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha.
abstract: Isoprostanes (IP) generated during free radical catalyzed oxidation injury have been claimed as a reliable indicator of oxidative stress in vivo. In particular, they are formed during LDL-oxidation. Vascular content, plasma levels and urinary excretion of IP were reported to be elevated in hypercholesterolemia. We therefore assessed the values of the IP 8-epi-PGF2alpha in plasma and urine in nine patients (7 males, 2 females) suffering from severe heterozygous hypercholesterolemia before and after LDL-apheresis as well as during the interval. LDL-apheresis caused a significant (P<0.01) drop in 8-epi-PGF2alpha in plasma and urine. The respective values in smokers (n = 4) were significantly (P<0.01) higher as compared to non-smokers. No sex difference was seen. Together with the findings of a parallel decrease in oxidized LDL, these data show a significant benefit of LDL-apheresis reducing in vivo oxidation injury. This benefit may at least partly contribute to the clinical improvement seen in the patients treated.
authors.affiliation: Department of Nuclear Medicine, University of Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Oguogho
authors.forename: A
authors.initials: A
authors.lastname: Ferlitsch
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001781:Blood Component Removal; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D014644:Genetic Variation; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy* / Q000652:urine; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D012907:Smoking; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013997:Time Factors
chemical_list: D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost